BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

179 related articles for article (PubMed ID: 21397998)

  • 1. Identification of novel potential antibiotics for tuberculosis by in silico structure-based drug screening.
    Izumizono Y; Arevalo S; Koseki Y; Kuroki M; Aoki S
    Eur J Med Chem; 2011 May; 46(5):1849-56. PubMed ID: 21397998
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Identification of novel antimycobacterial chemical agents through the in silico multi-conformational structure-based drug screening of a large-scale chemical library.
    Koseki Y; Kinjo T; Kobayashi M; Aoki S
    Eur J Med Chem; 2013 Feb; 60():333-9. PubMed ID: 23314046
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Inhibitors of FabI, an enzyme drug target in the bacterial fatty acid biosynthesis pathway.
    Lu H; Tonge PJ
    Acc Chem Res; 2008 Jan; 41(1):11-20. PubMed ID: 18193820
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Identification of compounds with potential antibacterial activity against Mycobacterium through structure-based drug screening.
    Kinjo T; Koseki Y; Kobayashi M; Yamada A; Morita K; Yamaguchi K; Tsurusawa R; Gulten G; Komatsu H; Sakamoto H; Sacchettini JC; Kitamura M; Aoki S
    J Chem Inf Model; 2013 May; 53(5):1200-12. PubMed ID: 23600706
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Structure-based design of a novel class of potent inhibitors of InhA, the enoyl acyl carrier protein reductase from Mycobacterium tuberculosis: a computer modelling approach.
    Subba Rao G; Vijayakrishnan R; Kumar M
    Chem Biol Drug Des; 2008 Nov; 72(5):444-9. PubMed ID: 19012578
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Discovery of InhA inhibitors with anti-mycobacterial activity through a matched molecular pair approach.
    Kanetaka H; Koseki Y; Taira J; Umei T; Komatsu H; Sakamoto H; Gulten G; Sacchettini JC; Kitamura M; Aoki S
    Eur J Med Chem; 2015 Apr; 94():378-85. PubMed ID: 25778993
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Development of antituberculous drugs: current status and future prospects].
    Tomioka H; Namba K
    Kekkaku; 2006 Dec; 81(12):753-74. PubMed ID: 17240921
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Piperazine derivatives: synthesis, inhibition of the Mycobacterium tuberculosis enoyl-acyl carrier protein reductase and SAR studies.
    Rotta M; Pissinate K; Villela AD; Back DF; Timmers LF; Bachega JF; de Souza ON; Santos DS; Basso LA; Machado P
    Eur J Med Chem; 2015 Jan; 90():436-47. PubMed ID: 25461892
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Identification of novel antitubercular compounds through hybrid virtual screening approach.
    Muddassar M; Jang JW; Hong SK; Cho YS; Kim EE; Keum KC; Oh T; Cho SN; Pae AN
    Bioorg Med Chem; 2010 Sep; 18(18):6914-21. PubMed ID: 20727773
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Combined effect of epigallocatechin gallate and triclosan on enoyl-ACP reductase of Mycobacterium tuberculosis.
    Sharma SK; Kumar G; Kapoor M; Surolia A
    Biochem Biophys Res Commun; 2008 Mar; 368(1):12-7. PubMed ID: 17996734
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Crystallographic and pre-steady-state kinetics studies on binding of NADH to wild-type and isoniazid-resistant enoyl-ACP(CoA) reductase enzymes from Mycobacterium tuberculosis.
    Oliveira JS; Pereira JH; Canduri F; Rodrigues NC; de Souza ON; de Azevedo WF; Basso LA; Santos DS
    J Mol Biol; 2006 Jun; 359(3):646-66. PubMed ID: 16647717
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phenylimidazole derivatives as specific inhibitors of bacterial enoyl-acyl carrier protein reductase FabK.
    Ozawa T; Kitagawa H; Yamamoto Y; Takahata S; Iida M; Osaki Y; Yamada K
    Bioorg Med Chem; 2007 Dec; 15(23):7325-36. PubMed ID: 17892940
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Synthesis of 4-phenoxybenzamide adenine dinucleotide as NAD analogue with inhibitory activity against enoyl-ACP reductase (InhA) of Mycobacterium tuberculosis.
    Bonnac L; Gao GY; Chen L; Felczak K; Bennett EM; Xu H; Kim T; Liu N; Oh H; Tonge PJ; Pankiewicz KW
    Bioorg Med Chem Lett; 2007 Aug; 17(16):4588-91. PubMed ID: 17560106
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Structural modification of a novel inhibitor for mycobacterium enoyl-acyl carrier protein reductase assisted by
    Taira J; Nagano T; Kitamura M; Yamaguchi M; Sakamoto H; Aoki S
    Int J Mycobacteriol; 2020; 9(1):12-17. PubMed ID: 32474482
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Development of 2-(4-oxoquinazolin-3(4H)-yl)acetamide derivatives as novel enoyl-acyl carrier protein reductase (InhA) inhibitors for the treatment of tuberculosis.
    Pedgaonkar GS; Sridevi JP; Jeankumar VU; Saxena S; Devi PB; Renuka J; Yogeeswari P; Sriram D
    Eur J Med Chem; 2014 Oct; 86():613-27. PubMed ID: 25218910
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Molecular dynamics simulation studies of the wild-type, I21V, and I16T mutants of isoniazid-resistant Mycobacterium tuberculosis enoyl reductase (InhA) in complex with NADH: toward the understanding of NADH-InhA different affinities.
    Schroeder EK; Basso LA; Santos DS; de Souza ON
    Biophys J; 2005 Aug; 89(2):876-84. PubMed ID: 15908576
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Marine natural products from the Turkish sponge Agelas oroides that inhibit the enoyl reductases from Plasmodium falciparum, Mycobacterium tuberculosis and Escherichia coli.
    Tasdemir D; Topaloglu B; Perozzo R; Brun R; O'Neill R; Carballeira NM; Zhang X; Tonge PJ; Linden A; Rüedi P
    Bioorg Med Chem; 2007 Nov; 15(21):6834-45. PubMed ID: 17765547
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Binding of the tautomeric forms of isoniazid-NAD adducts to the active site of the Mycobacterium tuberculosis enoyl-ACP reductase (InhA): a theoretical approach.
    Stigliani JL; Arnaud P; Delaine T; Bernardes-Génisson V; Meunier B; Bernadou J
    J Mol Graph Model; 2008 Nov; 27(4):536-45. PubMed ID: 18955002
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Structure-function analysis of the acyl carrier protein synthase (AcpS) from Mycobacterium tuberculosis.
    Dym O; Albeck S; Peleg Y; Schwarz A; Shakked Z; Burstein Y; Zimhony O
    J Mol Biol; 2009 Nov; 393(4):937-50. PubMed ID: 19733180
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Design and in silico screening of combinatorial library of antimalarial analogs of triclosan inhibiting Plasmodium falciparum enoyl-acyl carrier protein reductase.
    Frecer V; Megnassan E; Miertus S
    Eur J Med Chem; 2009 Jul; 44(7):3009-19. PubMed ID: 19217192
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.